Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease
Posted inCardiology news

Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease

The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, stroke, or major bleeding occurred in 16.6% vs 14.2% of patients, suggesting prasugrel may offer better outcomes in this high-risk population.
Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds
Posted inDiabetes & Endocrinology news Psychiatry

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds

A landmark Swedish cohort study of 95,490 patients reveals that semaglutide is associated with a 42% lower risk of worsening mental illness in people with depression and anxiety, while other GLP-1 receptor agonists show varied effects. The findings suggest potential dual therapeutic benefits for metabolic and mental health conditions.
Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies
Posted inDiabetes & Endocrinology news Psychiatry

Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies

A massive systematic review of 5.5 million patients reveals that those with mental disorders receive significantly lower quality diabetes care, including less frequent monitoring and a 74% lower likelihood of being prescribed GLP-1 receptor agonists compared to those without psychiatric conditions.
Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Posted inDiabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.